Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Etamsilate→

Etamsilate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2624-44-4
Molecular formula
C10H17NO5S
Molecular weight
263.31 g/mol
Drug class
Haemostatic agentcapillary-stabilising drug
Mechanism of action
Proposed to improve platelet adhesion and capillary endothelial stability and reduce capillary bleeding. The exact molecular mechanism and magnitude of clinical benefit are not fully established.
Indications / reported uses
  • Used in some countries for prevention or reduction of capillary bleeding, including selected surgical or gynaecological bleeding indications; availability and evidence vary by jurisdiction and it should not replace definitive haemostatic treatment

Sources: NLM MeSH — Etamsylate · PubMed — Etamsylate clinical efficacy · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Haemostatic agent; capillary-stabilising drug

Mechanism of action

Proposed to improve platelet adhesion and capillary endothelial stability and reduce capillary bleeding. The exact molecular mechanism and magnitude of clinical benefit are not fully established.

General use cases

  • Used in some countries for prevention or reduction of capillary bleeding, including selected surgical or gynaecological bleeding indications; availability and evidence vary by jurisdiction and it should not replace definitive haemostatic treatment

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Etamsilate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Etamsilate Permitted Daily Exposure (PDE) report (the Etamsilate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Etamsilate Occupational Exposure Limit (OEL) report (the Etamsilate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.